Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Change in Accured Expenses: 2013-2025

Historic Change in Accured Expenses for Ocular Therapeutix (OCUL) over the last 12 years, with Sep 2025 value amounting to $5.4 million.

  • Ocular Therapeutix's Change in Accured Expenses fell 4.05% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 million, marking a year-over-year increase of 501.21%. This contributed to the annual value of $3.6 million for FY2024, which is 370.63% up from last year.
  • Ocular Therapeutix's Change in Accured Expenses amounted to $5.4 million in Q3 2025, which was up 89.23% from $2.8 million recorded in Q2 2025.
  • In the past 5 years, Ocular Therapeutix's Change in Accured Expenses registered a high of $7.9 million during Q2 2024, and its lowest value of -$14.0 million during Q1 2024.
  • Over the past 3 years, Ocular Therapeutix's median Change in Accured Expenses value was $2.6 million (recorded in 2023), while the average stood at $680,273.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first surged by 930.32% in 2022, then tumbled by 433.90% in 2024.
  • Quarterly analysis of 5 years shows Ocular Therapeutix's Change in Accured Expenses stood at $188,000 in 2021, then spiked by 930.32% to $1.9 million in 2022, then crashed by 164.33% to -$1.2 million in 2023, then skyrocketed by 437.56% to $4.2 million in 2024, then decreased by 4.05% to $5.4 million in 2025.
  • Its Change in Accured Expenses stands at $5.4 million for Q3 2025, versus $2.8 million for Q2 2025 and -$5.1 million for Q1 2025.